FIELD: pharmaceuticals; physics.
SUBSTANCE: invention relates to pharmaceutical analysis, in particular to the analysis of materials using optical means. Method for quantitative determination of medicinal agents of a group of vastatines involves dissolving the analysed sample at room temperature and stirring until complete dissolution, treatment of an aliquot part of the prepared solution with chemical reagents followed by photoelectrocolorimetry of the obtained coloured solutions, quantitative determination of drug substances of the group of vastatines by calibration graphs, wherein the analysed sample is dissolved in methanol, an aliquot portion of the prepared solution is treated with a methanolic solution of nickel sulphate in concentrated hydrochloric acid at room temperature, the separated coloured precipitate is extracted with chloroform, dried over anhydrous sodium sulphate and photoelectrocolorimetry at wave length 590 nm.
EFFECT: what is offered is a method for quantitative determination of drug substances of a group of vastatines.
1 cl, 7 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR QUANTITATIVE DETERMINATION OF PIPERIDINE (BUTYROPHENONE GROUP) | 2018 |
|
RU2684101C1 |
METHOD FOR QUANTITATIVE DETERMINATION OF MEDICINAL AGENTS | 2014 |
|
RU2599102C2 |
METHOD OF QUANTITATIVE DETERMINATION OF 5-NITROIMIDAZOLE DERIVATIVES (NIDAZOLES GROUP) | 2018 |
|
RU2683783C1 |
METHOD OF QUANTITATIVE DETERMINATION OF BENZIMIDAZOLE DERIVATIVES (GROUP OF PRAZOLS) | 2018 |
|
RU2680521C1 |
METHOD FOR QUANTITATIVE DETERMINATION OF METHYLCARBAMATE BENZIMIDAZOLE DERIVATIVES | 2014 |
|
RU2589845C2 |
METHOD OF QUANTITATIVE DETERMINATION OF DIBENZAZEPINE DERIVATIVES (IPRAMINES GROUP) | 2015 |
|
RU2613876C1 |
METHOD FOR QUANTITATIVE DETERMINATION OF MEDICINAL AGENTS OF INDANDIONE-1,3 DERIVATIVES | 2014 |
|
RU2599103C2 |
METHOD FOR QUANTITATIVE DETERMINATION OF IMIDAZOLE DERIVATIVES (IMIDAZOLINE GROUP) | 2014 |
|
RU2597787C2 |
METHOD FOR QUANTITATIVE DETERMINATION OF DERIVATIVES OF IMIDAZOLE UNSUBSTITUTED IN 5-POSITION | 2015 |
|
RU2619857C2 |
PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF LIPID METABOLISM DISORDER | 2001 |
|
RU2246302C2 |
Authors
Dates
2019-06-10—Published
2018-04-23—Filed